Previously, bone anabolic therapy using parathyroid hormone (PTH) or anti‐sclerostin (Romosuzumab) showed improved bone outcomes in patients with metabolic disorders such as osteoporosis.20, 61, 62, 63 In addition, anti‐sclerostin therapy in preclinical models of myeloma using preventative treatment strategies have inhibited bone loss and increased bone strength,25, 63 highlighting that bone anabolic therapy could be of great benefit to patients with myeloma bone disease. The gene discussed is SOST; the disease is plasma cell myeloma.